| Identification | Back Directory | [Name]
PF-07338233 | [CAS]
2245880-46-8 | [Synonyms]
AV-006
ARX-1796
PF-07338233
ARX-1796（AV-006）
ethyl 3-(((((2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate | [Molecular Formula]
C14H23N3O8S | [MOL File]
2245880-46-8.mol | [Molecular Weight]
393.41 |
| Chemical Properties | Back Directory | [Boiling point ]
562.0±60.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
15.89±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Avibactam tomilopil (ARX-1796, AV-006) is an orally active prodrug of Avibactam and a β-lactamase inhibitor. Avibactam tomilopil can be used in the study of diseases such as urinary tract infections[1][2][3]. | [in vivo]
Avibactam tomilopil is used in combination with Ceftibuten (HY-B0698) for oral dosing and can be converted into active Avibactam in vivo. Avibactam can block enzymes produced by gram-negative bacteria and protect β-lactam antibiotics from degradation[1]. | [storage]
Store at -20°C | [References]
[1] Huband MD, et al. Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination. J Clin Microbiol. 2023 Jul 20;61(7):e0165722. DOI:10.1128/jcm.01657-22
[2] Veeraraghavan B, et al. Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections. Infect Dis Ther. 2021;10(4):1815-1835. DOI:10.1007/s40121-021-00509-4
[3] Falcone M, et al. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713-2722. DOI:10.1093/jac/dkw239 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|